<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02483182</url>
  </required_header>
  <id_info>
    <org_study_id>ZEP - 002 - IL</org_study_id>
    <nct_id>NCT02483182</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Parallel Group, Acyclovir-Controlled Study to Evaluate ZEP-3 Ointment for the Treatment of Cold Sores (Herpes Labialis).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shulov Innovate for Science Ltd. 2012</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shulov Innovate for Science Ltd. 2012</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, prospective, randomized, double-blind, parallel group,&#xD;
      acyclovir-controlled clinical study to evaluate the safety, tolerability and preliminary&#xD;
      therapeutic efficacy of ZEP-3 ointment 1.0% for the treatment of cold sores (Herpes&#xD;
      labialis), following five consecutive treatment days with five times daily topical&#xD;
      administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of this study are:&#xD;
&#xD;
        -  &quot;Time to healing&quot; - Clinician-assessed duration in days of herpes labialis episode.&#xD;
&#xD;
        -  Patient-assessed duration and intensity of pain by Visual Analog Scale (VAS).&#xD;
&#xD;
        -  Safety and tolerability following five consecutive treatment days with five times daily&#xD;
           topical administration.&#xD;
&#xD;
      The secondary endpoints of this study are:&#xD;
&#xD;
        -  Proportion of subjects with non - ulcerative herpes lesion.&#xD;
&#xD;
        -  Time for herpes labialis recurrences&#xD;
&#xD;
      Subject safety will be assessed following treatment by ZEP-3 ointment 1.0% or acyclovir cream&#xD;
      5% treatment, using measurements of the following variables:&#xD;
&#xD;
        -  Physical examination,&#xD;
&#xD;
        -  Vital Signs (HR, BP, Body temperature),&#xD;
&#xD;
        -  Adverse events recording and&#xD;
&#xD;
        -  Concomitant medications&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">June 24, 2018</completion_date>
  <primary_completion_date type="Actual">June 24, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician-assessed &quot;Time to healing&quot;</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for Herpes labialis recurrences</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Herpes Labialis</condition>
  <arm_group>
    <arm_group_label>ZEP-3 ointment 1.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acyclovir cream 5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZEP-3 ointment 1.0%</intervention_name>
    <arm_group_label>ZEP-3 ointment 1.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir cream 5%</intervention_name>
    <arm_group_label>Acyclovir cream 5%</arm_group_label>
    <other_name>Zovirax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Prior to enrollment in this study, candidates must meet ALL of the following inclusion&#xD;
        criteria:&#xD;
&#xD;
          1. Patients suffering from recurrent Herpes labialis with history of at least 3 cold&#xD;
             sores recurrences during the previous 12 months.&#xD;
&#xD;
          2. Participants, either male or female are between 18 and 75 years of age.&#xD;
&#xD;
          3. Patients arrive at the clinic with any symptom of an acute Herpes labialis episode.&#xD;
&#xD;
             Or, patients arrive at the clinic within 48 hours of treatment initiation for a&#xD;
             recurrent Herpes labialis episode.&#xD;
&#xD;
          4. Patients with previous Herpes labialis episode must be healed for at least 14 days&#xD;
             before baseline visit&#xD;
&#xD;
          5. Patients with no history of reaction to topical products.&#xD;
&#xD;
          6. Female subjects of childbearing potential must have a negative pregnancy test at&#xD;
             screening and agree to use a proper contraceptive method during the study.&#xD;
&#xD;
          7. Participant understands the nature of the procedure and is willing and able to comply&#xD;
             with all requirement of the protocol.&#xD;
&#xD;
          8. Patient is willing and able to provide written informed consent prior to any study&#xD;
             procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has abnormal skin conditions or significant facial hair at or near the&#xD;
             investigational area&#xD;
&#xD;
          2. Subject has any body piercing in or around the area ordinarily affected by cold sores.&#xD;
&#xD;
          3. Subjects with a history of cardiac abnormalities.&#xD;
&#xD;
          4. Subject has a recent history of renal dysfunction or serious hepatic disease&#xD;
&#xD;
          5. Subject has an active malignancy or immunodeficient disease&#xD;
&#xD;
          6. Subject who is unwilling to stop using topical medical, OTC, cosmetics or facial skin&#xD;
             care products in or around the oral area during the study period.&#xD;
&#xD;
          7. Subject requires chronic use of immunomodifying drugs or topical steroids on or near&#xD;
             the face.&#xD;
&#xD;
          8. Subject requires chronic use of anti-viral medication.&#xD;
&#xD;
          9. Subject requires chronic use of analgesics, pain medication or non-steroidal anti&#xD;
             inflammatory agents (NSAIDs).&#xD;
&#xD;
         10. History of allergic or adverse response to acyclovir, or any related anti-viral drug.&#xD;
&#xD;
         11. Subject has had an infection with HSV-1 isolates know to be resistant to acyclovir,&#xD;
             valacyclovir, famciclovir, or ganciclovir.&#xD;
&#xD;
         12. Subject has had a herpes vaccine.&#xD;
&#xD;
         13. Females during pregnancy, lactation or breastfeeding.&#xD;
&#xD;
         14. Subject has a history of alcoholism or drug abuse within the preceding 12 months.&#xD;
&#xD;
         15. Subject is currently enrolled in another clinical trial involving the use of a drug&#xD;
             and/or a device.&#xD;
&#xD;
         16. Any history which, in the Investigator's judgment, makes the subject ineligible or&#xD;
             places the subject at undue risk.&#xD;
&#xD;
         17. Subjects with immune deficiency conditions including acquired immune deficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shemer Avner, Prof., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology out-patients clinic, Lev Hayasmin - Medical center, Natanya, ISRAEL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology out-patients clinic, Lev Hayasmin MC</name>
      <address>
        <city>Netanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>June 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes labialis, Cold sores, ZEP-3 ointment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Labialis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

